Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Personalized CAR-T cells (Xuanwu Hospital)
- Development stage
- Unknown
- Lead developer
- Xuanwu Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous, Intracranial
01
Overview
This personalized chimeric antigen receptor (CAR) T-cell therapy is an autologous cell-based immunotherapy developed by Xuanwu Hospital, Beijing, in collaboration with several biotechnology firms. The treatment involves engineering a patient's own T cells using a lentiviral vector to express CARs specific to one or more tumor-associated antigens, including EGFRvIII, IL13Rα2, HER2, EphA2, CD133, and GD2, depending on the individual's tumor expression profile. The therapy may also be designed to express anti-PD-L1 antibodies to enhance anti-tumor activity within the immunosuppressive microenvironment of malignant gliomas. It is currently being investigated in a Phase 1 pilot study for patients with recurrent high-grade gliomas, such as glioblastoma and anaplastic astrocytoma.
- Other names
- Personalized CAR-T for Recurrent Malignant Gliomas
02
Targets
CD133 (CD133 antigen)EGFRvIII (Epidermal growth factor receptor variant III)EPHA2 (Ephrin type-A receptor 2)GD2ERBB2 (Erb-b2 receptor tyrosine kinase 2)IL13RA2 (Interleukin-13 receptor subunit alpha 2)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on Personalized CAR-T cells (Xuanwu Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Personalized CAR-T cells (Xuanwu Hospital).